[{"orgOrder":0,"company":"Invitae","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Invitae","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Invitae \/ BridgeBio Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Invitae \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Invitae","sponsor":"Praxis Bioresearch","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PRAX-222","moa":"SCN2A","graph1":"Neurology","graph2":"IND Enabling","graph3":"Invitae","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invitae \/ Invitae","highestDevelopmentStatusID":"5","companyTruncated":"Invitae \/ Invitae"}]

Find Clinical Drug Pipeline Developments & Deals by Invitae

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Immuno
                          Not Confirmed
                          Immuno
                          Not Confirmed

                          Details : The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 30, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Discovery

                          Sponsor : BridgeBio Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          German Catalysts Meet
                          Not Confirmed
                          German Catalysts Meet
                          Not Confirmed

                          Details : PRAX-222 is an ASO designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-seizure-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations.

                          Product Name : PRAX-222

                          Product Type : Oligonucleotide

                          Upfront Cash : Inapplicable

                          September 20, 2022

                          Lead Product(s) : PRAX-222

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Recipient : Praxis Bioresearch

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank